

Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 – 3rd Interim Announcement

In the period from January 16, 2023 up to and including January 20, 2023, PharmaSGP Holding SE bought back a total of 256 shares of PharmaSGP Holding SE under the share buyback program; on January 3, 2023, PharmaSGP Holding SE disclosed pursuant to Art. 2 Sec. 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on January 4, 2023.

The overall volume of the shares bought back daily in the period from January 16, 2023 up to and including January 20, 2023 and the daily volume-weighted average stock market prices of the shares are as follows:

Date	Aggregate volume	Weighted average price (EUR)
January 16, 2023	90	25.1111
January 17, 2023	85	25.7000
January 18, 2023	81	25.4124
January 19, 2023	-	-
January 20, 2023	-	-
In total	256	25.4020

The total number of shares which have been bought back under the buyback program from January 4, 2023 up to and including January 20, 2023 thus amounts to 1060 shares.

The purchase of the PharmaSGP Holding SE shares was carried out by a bank commissioned by PharmaSGP Holding SE and exclusively via the Frankfurt Stock Exchange (XETRA trading).

More detailed information pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available on the internet at <https://ir.pharmasgp.com> at share buyback 2023.

Gräfelfing, January 20, 2023

PharmaSGP Holding SE
The Management Board